



1646  
JCW

PATENT  
Attorney Docket No. LEX-009DV

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT(S): Lo *et al.*  
SERIAL NO.: 09/977,034 GROUP NO.: 1646  
FILING DATE: October 11, 2001 EXAMINER: D. Jiang  
TITLE: Methods of Treating a Condition by Administration of Fc-Interferon-Alpha Fusion Protein

**CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8**

I hereby certify that this correspondence, and any document(s) referred to as enclosed herein, are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this 8th day of March, 2005.


  
\_\_\_\_\_  
Brenda L. MacLean

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith are:

1. Transmittal Form (1 page);
2. Power of Attorney by Assignee of Entire Interest/Revocation of Prior Powers and New Power of Attorney (1 page);
3. and a return receipt postcard.



**TRANSMITTAL  
FORM**

Application Serial Number	09/977,034
Filing Date	October 11, 2001
First Named Inventor	Lo
Group Art Unit	1646
Examiner Name	D. Jiang
Attorney Docket No.	LEX-009DV
Confirmation No.	4315

**ENCLOSURES (check all that apply)**

<input type="checkbox"/> Fee Transmittal Form <ul style="list-style-type: none"> <li><input type="checkbox"/> Check Attached</li> <li><input type="checkbox"/> Copy of Fee Transmittal Form</li> </ul>	<input type="checkbox"/> Copy of Notice to File Missing Parts of Application <ul style="list-style-type: none"> <li><input type="checkbox"/> Formal Drawing(s)</li> </ul>	<input type="checkbox"/> Notice of Appeal to Board of Patent Appeals and Interferences <ul style="list-style-type: none"> <li><input type="checkbox"/> Appeal Brief (in triplicate)</li> </ul>
<input type="checkbox"/> Amendment/Response <ul style="list-style-type: none"> <li><input type="checkbox"/> Preliminary</li> <li><input type="checkbox"/> After Final</li> <li><input type="checkbox"/> Affidavits/declaration(s)</li> <li><input type="checkbox"/> Letter to Official Draftsperson</li> </ul> including Drawings [Total Sheets ____]	<input type="checkbox"/> Request For Continued Examination (RCE) Transmittal <ul style="list-style-type: none"> <li><input checked="" type="checkbox"/> Power of Attorney By Assignee of Entire Interest/Revocation of Prior Powers and New Power of Attorney (1 page)</li> </ul>	<input type="checkbox"/> Status Inquiry <ul style="list-style-type: none"> <li><input checked="" type="checkbox"/> Return Receipt Postcard</li> <li><input checked="" type="checkbox"/> Certificate of First Class Mailing under 37 C.F.R. 1.8 (1 page)</li> </ul>
<input type="checkbox"/> Petition for Extension of Time	<input type="checkbox"/> Terminal Disclaimer <ul style="list-style-type: none"> <li><input type="checkbox"/> Executed Declaration and Power of Attorney for Utility or Design Patent Application</li> </ul>	<input type="checkbox"/> Certificate of Facsimile Transmission under 37 C.F.R. 1.8 <ul style="list-style-type: none"> <li><input type="checkbox"/> Additional Enclosure(s) (please identify below)</li> </ul>
<input type="checkbox"/> Information Disclosure Statement <ul style="list-style-type: none"> <li><input type="checkbox"/> Form PTO-1449</li> <li><input type="checkbox"/> Copies of IDS Citations</li> </ul>	<input type="checkbox"/> Small Entity Statement <ul style="list-style-type: none"> <li><input type="checkbox"/> CD(s) for large table or computer program</li> </ul>	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Amendment After Allowance <ul style="list-style-type: none"> <li><input type="checkbox"/> Request for Certificate of Correction</li> <li><input type="checkbox"/> Certificate of Correction (in duplicate)</li> </ul>	
<input type="checkbox"/> Sequence Listing submission <ul style="list-style-type: none"> <li><input type="checkbox"/> Paper Copy/CD</li> <li><input type="checkbox"/> Computer Readable Copy</li> <li><input type="checkbox"/> Statement verifying identity of above</li> </ul>		

**CORRESPONDENCE ADDRESS**

Direct all correspondence to: Patent Administrator  
 Kirkpatrick & Lockhart Nicholson  
 Graham LLP  
 75 State Street  
 Boston, MA 02109-1808  
 Tel. No.: (617) 261-3100  
 Fax No.: (617) 261-3175

**SIGNATURE BLOCK**

Respectfully submitted,

Brian A. Fairchild  
 Attorney for Applicants  
 Kirkpatrick & Lockhart Nicholson  
 Graham LLP  
 75 State Street  
 Boston, MA 02109-1808



PATENT  
Attorney Docket No. LEX-009DV

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INVENTORS: Lo et al. ASSIGNEE: EMD Lexigen Research Center Corp.

SERIAL NO.: 09/977,034 FILING DATE: October 11, 2001

TITLE: Methods of Treading a Condition by Administration of Fc-Interferon-Alpha Fusion Protein

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST**  
**REVOCATION OF PRIOR POWERS AND NEW POWER OF ATTORNEY**

Sir:

As an authorized representative of the assignee of record of the entire right, title, and interest in the above-identified patent application, I hereby revoke all powers of attorney previously given and hereby appoint the registered patent practitioners associated with **Customer Number 022832** to prosecute and transact all business in the U.S. Patent and Trademark Office connected therewith.

Please direct all correspondence for the above-identified patent application to the address associated with the above Customer Number.


The assignee of record of the entire right, title, and interest in the above-identified patent application is EMD Lexigen Research Center Corp., by virtue of the chain of title from the inventors of the above-identified patent application to the current assignee, as shown below:

By assignment on September 11, 2000, from inventors Kin-Ming Lo, Yaping Sun, and Stephen D. Gillies to Lexigen Pharmaceuticals Corp., recorded in the U.S. Patent and Trademark Office on November 5, 2003, at Reel No. 014656, Frame No. 0444; and

By change of corporate name from Lexigen Pharmaceuticals Corp. to EMD Lexigen Research Center Corp., on May 30, 2002, recorded in the U.S. Patent and Trademark Office on December 19, 2003, at Reel No. 014815, Frame No. 0751.

Respectfully submitted,

Dated: 3/3/2005

  
\_\_\_\_\_  
Stephen D. Gillies, Ph.D.  
President  
EMD Lexigen Research Center Corp.  
Bedford Campus  
45A Middlesex Turnpike  
Billerica, MA 01821